McKenna's Pharmacology for Nursing, 2e

983

Index

H Haemodynamics, 696, 697–698 Haemolytic crisis, 169

Hepatitis C drugs for, 144–146 Hepatoxicity, 36 Herbal medicine, 63–64 alternative therapies. See Alternative and complementary therapies ephedra, 459 Heroin, 67 Herpes and cytomegalovirus, 126, 132 agents for, 127, 132–134 adverse effects, 133 care considerations, 134 contraindications and cautions, 133 drug–drug interactions, 133–134 pharmacokinetics, 133 therapeutic actions and indications, 132 cytomegalovirus immunoglobulin, 286 Hexachlorphene, 950 Hexamine hippurate, 821 Hiccoughs, intractable, 929, 932 High-ceiling diuretics, 803, 809 High-density lipoproteins (HDLs), 729, 732 Hindbrain, 292, 298 Hirsuitism, 627, 630 Histamine, 231–232 Histamine-2 antagonists, 896, 897, 899–904 adverse effects, 901, 903 care considerations, 903–904 contraindications and cautions, 901 critical thinking scenario, 902–903 drug–drug interactions, 903 pharmacokinetics, 901 therapeutic actions and indications, 897, 901 Histamine-2 receptors, 888, 891 Histocompability antigens, 72, 74 HIV and AIDS, 126, 128 agents for, 127, 134–144 care considerations, 142 CCR5 coreceptor antagonist, 126, 136, 141 critical thinking scenario, 143–144 education, 138 integrase inhibitor, 126, 136, 141–142 non-nucleoside reverse transcriptase inhibitors, 126, 135, 136 adverse effects, 135 contraindications and cautions, 135 drug–drug interactions, 135 pharmacokinetics, 135 therapeutic actions and indications, 135 nucleoside reverse transcriptase inhibitors, 126, 135–139 adverse effects, 138 contraindications and cautions, 137–138 drug–drug interactions, 138–139 pharmacokinetics, 137 therapeutic actions and indications, 137 fixed combination drugs, 139 fusion inhibitor, 126, 136, 140

protease inhibitors, 126, 139–140 adverse effects, 140 contraindications and cautions, 139–140 drug–drug interactions, 140 pharmacokinetics, 139 therapeutic actions and indications, 139 Hives, 33–34 HMG-CoA reductase inhibitors, 737–738, 740–743 adverse effects, 741 care considerations, 741–742 contraindications and cautions, 741 drug–drug interactions, 741 hydroxymethylglutaryl-coenzyme A (HMG-CoA), 729, 733 pharmacokinetics, 741 therapeutic actions and indication, 740 Homatropine, 957 Home care, 65 Hookworm infections, 180, 181 hookworms, 179 Hop, 965 Horehound, 965 Hormone modulators, 191, 212–216, 513–514 adverse effects, 215 care considerations, 216 contraindications and cautions, 212 drug–drug interactions, 215 pharmacokinetics, 212 releasing hormones or factors, 514 therapeutic actions and indications, 212 Hormone replacement therapy (HRT), 612–613 Hormones, 512, 513 inhibiting, 516 stimulating, 516 Horse chestnut seed, 965 Human fibrin sealant, 767, 769 Human immune response, 83–84 Human papillomavirus (HPV), 274 recombinant, quadrivalent, 280 Human sexual response, 603–604 Hyaluronidase derivatives, 253–254 Hydantoins, 356–358 adverse effects, 358 contraindications and cautions, 358 drug–drug interactions, 358 pharmacokinetics, 356 therapeutic actions and indications, 356 Hydralazine, 666, 674 Hydrochloric acid, 888, 891 Hydrochlorothiazide, 675, 803, 805–808 Hydrocodone, 401 Hydrocortisone, 539, 542, 543, 543, 547, 954, 957 Hydromorphone, 402 Hydrostatic pressure, 650 Hydroxocobalamin, 775, 787, 788 Hydroxychloroquine, 163, 166–167, 169 Hydroxymethylglutaryl-coenzyme A (HMG-CoA). See HMG-CoA reductase inhibitors

Haemophilus B conjugate vaccine, 279 Haemophilus influenzae B, 274, 279 Haemopohilia, 767 Haemoptysis, 681, 684 Haemorheologic agent, 751, 758, 767 Haemorrhagic disorders, 750, 754 Haemostatic agents, 750, 751, 767, 769–771 adverse effects, 770 care considerations, 770–771 contraindications and cautions, 770 drug–drug interactions, 770 pharmacokinetics, 769–770 systemic, 769–770 therapeutic actions and indications, 769 topical, 769–770 Hageman factor, 228, 231, 750, 753 Half-life, 15, 24–25 calculations, 24 Haloperidol, 200, 335–337, 345 Halothane, 422 Hamamelis water, 950 Hawthorn, 965 HDLs (high-density lipoproteins), 729, 732 Headaches. See Migraine headache Healthcare pattern, 44 Heart block, 696, 699 Heart disease anticholinergic drugs, 508–509 women and, 732 Heart failure, 652–653, 681, 682–685 cellular changes, 683 clinical manifestations, 683–684 compensatory mechanisms, 683 diuretic agents, using, 812–813 left-sided, 684 right-sided, 684 treatments, 684–685 Heart, structure and function, 643–646 automaticity, 642, 644–645 autonomic influences, 645–646 cardiac conduction, 644–646 cardiac cycle, 642, 643–644 conductivity, 642, 645 myocardial contraction, 646 Helminths, 179, 180 Helper T cells, 126, 134, 233 Heparin, 751, 752, 754, 756, 759–760, 762–764 low-molecular-weight, 751, 757, 766 overdose, 763 Hepatic enzyme system, 23 drugs that alter, 23 Hepatic microsomal system, 15, 23 Hepatitis A, 274 vaccine, inactivated, 280 hepatitis B recombinant vaccine, with, 280 Hepatitis B, 126, 274 drugs for, 144–146 vaccine, 280 Hepatitis B immune globulin, 286